LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced preliminary net sales results for the th…
Author: Business Wire
Viridian Therapeutics Announces Royalty Financing with DRI Healthcare for up to $300 Million
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potentially best-in-class medicines for serious and rare diseases, today announced it entered in…
Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy (ADOA)
BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicines, today announced the presentation of two-year data from th…
Glaukos Announces FDA Approval of Epioxa™
ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U…
Aurion Biotech Achieves All Primary, Secondary, and Exploratory Endpoints in AURN001 Phase 1/2 CLARA Trial at 12 Months
SEATTLE & CAMBRIDGE, Mass. & TOKYO–(BUSINESS WIRE)– #AAO2025–Aurion Biotech, a clinical-stage regenerative medicine company with a mission to restore vision to millions of patients, today announced positive 12 month results from the company’s Phase …
Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today results from two Phase III studies evaluating the efficacy and safety of two doses of investigational vamikibart (0.25 an…
Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
BOSTON–(BUSINESS WIRE)–Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors
Dompés Programm zu NAION wird für richtungsweisendes FDA-Programm Commissioner’s National Priority Voucher ausgewählt
MAILAND & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, ein führendes biopharmazeutisches Unternehmen mit Niederlassungen in Italien und den USA, gab heute bekannt, dass es von der US-amerikanischen Food and Drug Administration (FDA) für die Teilnahme am …
Het programma van Dompé voor NAION geselecteerd voor het baanbrekende FDA Commissioner’s National Priority Voucher programma
MILAAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, een toonaangevend biofarmaceutisch bedrijf met activiteiten in Italië en de VS, heeft vandaag bekendgemaakt dat het door de Amerikaanse Food and Drug Administration (FDA) is geselecteerd om deel te ne…
Il programma di Dompé sulla NOIA-NA selezionato per il prestigioso programma Commissioner’s National Priority Voucher della FDA
MILANO & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, un’azienda biofarmaceutica leader con sedi operative in Italia e negli Stati Uniti, oggi ha annunciato di essere stata selezionata dalla Food and Drug Administration (FDA) statunitense per partecipare…
Le programme de Dompé dans le domaine de la NAION sélectionné pour le programme national prioritaire du commissaire de la FDA
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, une société biopharmaceutique de premier plan implantée en Italie et aux États-Unis, a annoncé aujourd’hui avoir été sélectionnée par la Food and Drug Administration (FDA) américaine pour participer au…
Seleccionan el programa de Dompé en NAION para el emblemático programa Acerca del programa piloto de Vales de Prioridad Nacional del Comisionado de la FDA
MILAN Y SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé, una biofarmacéutica líder con operaciones en Italia y Estados Unidos, ha anunciado hoy que ha sido seleccionada por la Administración de Alimentos y Medicamentos de Estados Unidos (FDA) para participar…
Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program
MILAN & SAN MATEO, Calif.–(BUSINESS WIRE)–Dompé earns FDA Commissioner’s Priority Voucher to fast-track its NGF therapy for NAION, accelerating review of a potential vision-saving treatment.
STAAR Surgical Affirms that No Acquisition Proposals Have Been Received From Any Party Other Than Alcon
LAKE FOREST, Calif.–(BUSINESS WIRE)–STAAR Surgical Company (NASDAQ: STAA) (“STAAR”), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today issued the following statement: Broadwoo…
Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®)
FAR HILLS, N.J.–(BUSINESS WIRE)– #AMD–Samsara Vision Expands U.S. and Puerto Rico Clinical Study Sites for the Smaller-Incision New-Generation Implantable Miniature Telescope (SING IMT®)
IntrinsiQ Specialty Solutions Expands Data Capabilities to Empower Biopharmaceutical Manufacturers and Physicians with Actionable Insights to Improve Patient Outcomes
CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–IntrinsiQ® Specialty Solutions (IntrinsiQ), a leader in data analytic solutions, and part of Cencora, can now offer expanded data and insights for oncology, retina and other therapeutic areas. As part of this expansi…
Y.ora Vision Launches Following Licensing Agreement Between SERI and Eyexora Global to Advance Minimally Invasive Glaucoma Surgery
SINGAPORE–(BUSINESS WIRE)– #glaucoma–Y.ora Vision Launches Following Licensing Agreement Between SERI and Eyexora Global to Advance Minimally Invasive Glaucoma Surgery
Heru Surpasses 1 Million Eyes Tested, Cementing Leadership in AI-Powered Vision Diagnostics
MIAMI–(BUSINESS WIRE)– #automation–Heru, the leader in AI-powered vision diagnostics, today announced it has surpassed a landmark achievement of one million eyes tested on its wearable platform. This significant milestone underscores the company’s a…
Warby Parker to Announce Third Quarter 2025 Financial Results November 6, 2025
NEW YORK–(BUSINESS WIRE)–Warby Parker Inc. (NYSE: WRBY) (the “Company”), a direct-to-consumer lifestyle brand focused on vision for all, today announced that its financial results for the third quarter ended September 30, 2025 will be released before…
PolyActiva to Present Advancements in Next-Generation Ocular Micro-Implant Technology at Eyecelerator® @ AAO 2025
FORT WORTH, Texas & MELBOURNE, Australia–(BUSINESS WIRE)–PolyActiva, a clinical-stage biopharmaceutical company pioneering a novel drug delivery technology to improve outcomes for patients with ocular conditions, today announced that Michael Brubaker…